Drug development hiring lives at the seam between science, regulatory, and manufacturing — and no other function in biotech has as many failure modes for a wrong hire. Recruits Lab runs drug development searches with recruiters who can distinguish real program-owning experience from resume-strong translational-adjacent work.
Drug development is the longest, most expensive, and most failure-prone process in industry. Every hire matters disproportionately. A single weak link in CMC, regulatory, or clinical operations can delay an IND, an NDA, or a BLA by 6 to 18 months — and at venture-backed economics, that delay often translates directly into a missed runway milestone.
Recruits Lab places drug development leadership for biotech and specialty pharma companies running programs from late discovery through commercial launch. We work across modalities — small molecule, biologics, ADCs, RNA, cell, and gene therapy — and across every functional area of development: translational medicine, DMPK, toxicology, CMC, clinical operations, clinical development, regulatory affairs, medical affairs, and program management.
Our recruiters know the difference between a translational lead who has actually owned a successful IND filing and one who has only contributed to one. They know which clinical development VPs have run pivotal trials and which have only supported them. They know which regulatory leaders have managed a successful pre-NDA meeting and which have not. That depth is the only thing that prevents the long, expensive mishire.
Most generalist firms cannot make those distinctions. They submit resumes that look right on paper and let your team do the work of figuring out who actually has the experience. We do that work first. Every candidate that hits your shortlist has been screened for the specific submission, modality, or trial phase you need.
And we do it on subscription pricing, not legacy 25 percent contingency. That math matters when you are building out a development team and need to make five hires in a single quarter without burning a million dollars in recruiting fees.
Why this market is hard to recruit for. And how we solve each one.
Candidates who have actually owned an IND, NDA, BLA, or MAA filing front-to-back are a small minority of the resumes that claim that experience. We screen for true ownership, not adjacency.
ADC, LNP, mRNA, AAV, and autologous cell therapy each have their own process and regulatory requirements. We map candidates to your modality, not a generic 'biologics' bucket.
Top development leaders are courted constantly. Slow internal interview cycles lose them to faster-moving competitors. We coach hiring teams on velocity from kickoff.
Big pharma development leaders often struggle in pre-clinical or Phase 1 environments. We pre-qualify candidates on stage fit — not just title and tenure.
CRO-experienced candidates can transition to sponsor work, but the move requires cultural calibration. We screen explicitly for the move.
Development leaders coming from big pharma rarely value startup equity correctly out of the gate. We translate the offer in plain numbers so the upside is clear.
The repeatable system behind our 14-day average hire time.
We run a deep intake call with hiring managers and scientific leadership covering technical must-haves, dealbreakers, comp band, equity philosophy, and the cultural traits that predict success in your specific stage and program.
We build a fresh map of 80-150 qualified candidates from direct competitors, academic spinouts, CROs, and adjacent therapeutic areas. No database scraping — real research from a recruiter who understands the science.
Personalized outreach from a senior recruiter who can actually discuss your molecule, mechanism, or modality. Response rates run 3-5x higher than generalist agencies because the first message reads like it came from another scientist.
Five to eight vetted candidates with structured profile briefs covering technical fit, motivation, publication record where relevant, comp expectations, and risk factors. Not a resume dump — a decision document.
We manage offer construction, counter-offer scenarios, resign coaching, and start-date negotiation. Every placement carries a 90-day replacement guarantee at no additional fee.
Original observations from live searches in this specialty.
The single most reliable screen for a drug development leader is: 'Walk me through a program you personally moved from lead optimization into IND-enabling, and name the three decisions where you were the tiebreaker.' Candidates who cannot narrate that at concrete detail are not the seniors they present as.
Not every CRO-side drug development leader struggles on sponsor side. The ones who ran the sponsor-side relationship at their CRO, argued back on go/no-go calls, and built regulatory strategy typically transition cleanly. We split the CRO pool on that axis rather than filtering it out wholesale.
Directors of Drug Development with real depth in one modality (small molecule vs. biologic vs. cell/gene) rarely deliver in another modality even at the same seniority. We do not put a small-molecule director in front of a gene therapy hiring manager without explicit alignment on why the hiring manager wants the cross-training.
2026 U.S. base salary ranges for drug development roles at venture-backed and mid-cap life sciences companies. Excludes equity, bonus, and sign-on. Ranges reflect Series A through commercial-stage benchmarks.
| Role | Base Salary Range |
|---|---|
| Director, Translational Medicine | $240K–$310K |
| Director, CMC | $220K–$290K |
| Director, Clinical Operations | $210K–$275K |
| Director, Regulatory Affairs | $220K–$285K |
| VP, Clinical Development | $310K–$420K |
| Head of Pharmacovigilance | $240K–$310K |
| Chief Development Officer | $425K–$600K |
Source: Recruits Lab 2026 Life Sciences Compensation dataset.
Quick answers to the questions founders and hiring leaders ask most.
A drug development recruiter sources and qualifies leadership talent across translational, CMC, clinical, and regulatory functions for biotech and pharma programs running between IND and commercial approval. Recruits Lab specializes in this work and averages 14 days from kickoff to signed offer.
Industry average is 90 to 150 days for director and VP-level development roles. Recruits Lab averages 14 days for the same searches through active sourcing and disciplined interview cadence.
Legacy contingency firms charge 22 to 30 percent of first-year base, which often exceeds $80,000 per hire at the director level. Recruits Lab offers a flat monthly subscription starting at $7,500 with unlimited active roles or a 20 percent contingency with a 90-day guarantee.
Yes. CMC is one of our highest-volume drug development practice areas, including process development, analytical, formulation, MSAT, and quality.
Yes. We routinely build out clinical operations, biostatistics, medical monitoring, and regulatory teams ahead of pivotal trial start. Subscription pricing scales well to multi-hire builds.
Six development leadership hires needed in 90 days ahead of a Phase 2 readout. Internal recruiting team had filled one role in the prior quarter.
Subscription engagement with a dedicated senior recruiter and two associate recruiters. Calibrated four parallel searches in week 1, scoped two more in week 4, and ran weekly sprints with the hiring team.
Five of six roles filled inside 90 days. Final hire closed in day 102. Total fee was less than one retained-search placement at legacy contingency rates.
"Recruits Lab understood the science from day one. They sent four interview-ready candidates inside two weeks after our internal team had spent three months on the role."
"Their subscription model let us close three scientific hires in a single quarter for less than what a single retained search would have cost us."
Yes. We staff specialized recruiters for both modalities and pair them with the engagement based on your portfolio.
Yes. We screen specifically for the cultural and operational shifts required to move from CRO to sponsor environments.
Yes. PM and project leadership across discovery, CMC, and clinical are routine searches for us.
Pre-Series A through commercial launch. Subscription pricing is designed for the budgets earlier-stage programs typically have.
We focus on permanent placements. We can refer trusted interim partners when that is the right fit.
Every placement carries a 90-day replacement guarantee. If a hire leaves or does not work out within the first 90 days, we run the search again at no additional fee.
Yes. We sign NDAs and routinely run confidential and stealth-mode searches for executive replacements, sensitive program leads, and pre-launch hires.
Book a free 30-minute hiring strategy review using the CTA on this page. We will scope the role, suggest a sourcing approach, and quote a subscription or contingency option that fits your stage.
Compensation data, hiring playbooks, case studies, and related recruiting specialties.
Four ways to engage. Pick whichever matches where you are.
30-minute strategy review with a senior recruiter. Free, no commitment.
Get startedTell us about the role. We respond with a calibration call within 24 hours.
Get startedSend a job description. We confirm fit and quote a subscription or contingency engagement.
Get startedSenior candidates: get represented to our active hiring pipeline.
Get startedRelated Resources
Hand-picked salary guides, market reports, and recruiter pages related to this topic. Authored by Darren Nelson and the Recruits Lab team.
Schedule a free 30-minute Hiring Strategy Review and walk away with a clear plan tailored to your roles.